Cerebral Infarction, Ischemic Cerebrovascular Disease, Nervous System Diseases, Stroke
Conditions
Keywords
Vascular Diseases, Ticagrelor
Brief summary
This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study is to establish a population pharmacokinetic model of ticagrelor , explore the correlation between its blood concentration and the events of ischemia and the adverse effects of hemorrhage, and evaluate the effectiveness and safety of ticagrelor in the treatment of ischemic cerebrovascular disease.
Detailed description
Ischemic stroke and transient ischemic attack are the most common types of ischemic cerebrovascular disease. Patients will suffer from physiological function damage, even mental symptoms, social function and other obstacles, seriously affecting the quality of life, and bringing heavy burden to families and society. Ticagelor is a new P2Y12 receptor antagonist. Compared with clopidogrel, ticagelor has stronger and more lasting platelet inhibition, and can reduce the recurrence of ischemic events in patients with acute coronary syndrome . Therefore, at least 50 patients with ischemic cerebrovascular disease using ticagelor will be included. Before and after treatment, the laboratory examination data, NIHSS, mRS, combined medication and adverse events, and ischemic events of the patients will be collected. The population pharmacokinetics model of Ticagelor was established to evaluate its effectiveness and safety.
Interventions
None listed
Sponsors
Qianfoshan Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female or male aged ≥ 18 years. 2. Clinically diagnosed as ischemic cerebrovascular disease. 3. Take ticagelor for antiplatelet therapy. 4. Provision of informed consent.
Exclusion criteria
1. Head CT or MRI suggests the presence of intracranial hemorrhagic disease. 2. People with tumors and other serious systemic diseases. 3. Allergy to ticagelor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between blood drug concentration and adverse events | 6 months | Try to find the relationship between pharmacokinetic parameters and adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of adverse events caused by treatment | 6 months | In a clinical trial, the probability of an unexpected and adverse medical event that occurs after a patient or clinical subject receives a trial drug, but it does not necessarily have a causal relationship with the treatment. |
| NIHSS | 6 months | NIH stroke scale (NIHSS) to assess the degree of neurological deficit in stroke patients. The score ranges from 0 to 42 points, the higher the score, the more severe the nerve damage. Patients with a baseline assessment of\> 16 points are likely to die, while those with a score of \<6 are likely to recover well; for each additional point, the probability of a good prognosis is reduced by 17% |
| mRS | 6 months | Modified Rankin scale (mRS) is an indicator of the efficacy of functional disability. The score ranges from 0 to 5 points, and the clinical score will be increased to 6 points to indicate death. The higher the score, the more disability the patient is. |
Contacts
Primary ContactHuang Xin
Outcome results
None listed